Previous Article | Next Article 
Journal of Virology, December 2001, p. 12347-12358, Vol. 75, No. 24
0022-538X/01/$04.00+0 DOI: 10.1128/JVI.75.24.12347-12358.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.
A Human Herpesvirus 7 Glycoprotein, U21, Diverts
Major Histocompatibility Complex Class I Molecules to
Lysosomes
Amy W.
Hudson,*
Peter
M.
Howley, and
Hidde L.
Ploegh
Department of Pathology, Harvard Medical
School, Boston, Massachusetts 02115
Received 24 July 2001/Accepted 12 September 2001
 |
ABSTRACT |
All members of the herpesvirus family persist in their host
throughout life. In doing so, herpesviruses exploit a surprising number
of different strategies to evade the immune system. Human herpesvirus 7 (HHV-7) is a relatively recently discovered member of the herpesvirus
family, and little is known about how it escapes immune detection. Here
we show that HHV-7 infection results in premature degradation of major
histocompatibility complex class I molecules. We identify and
characterize a protein from HHV-7, U21, that binds to and diverts
properly folded class I molecules to a lysosomal compartment. Thus, U21
is likely to function in the normal course of HHV-7 infection to
downregulate surface class I molecules and prevent recognition of
infected cells by cytotoxic T lymphocytes.
 |
INTRODUCTION |
Human herpesvirus 7 (HHV-7) is a
betaherpesvirus most closely related to HHV-6. HHV-7 and HHV-6 have
colinear genomes and share many biological properties. Both viruses
display CD4+ T lymphotropism, both cause xanthem
subitum (roseola) (5, 29, 32), and more than 90% of
adults are seropositive for both HHV-6 and HHV-7 (38).
HHV-6 and -7-infected cells exhibit cytomegaly and are prone to
syncytium formation, features reminiscent of those seen in human
cytomegalovirus (HCMV) infection. The sequences of HHV-6 and -7 genomes
confirm their relationship to HCMV (25).
Little is known about the immunobiology of HHV-6 or -7. Like all other
herpesviruses, HHV-6 and -7 remain latent or establish persistent
infections. To do so, they must avoid detection and elimination by the
immune system. Viral immune evasion strategies include restriction of
viral gene expression, infection at immunoprivileged sites, obstruction
of antiviral cytokine function, and interference with antigen
presentation (34). Notably, all of the herpesviruses thus
far examined employ the latter strategy of interfering with viral
antigen presentation to cytotoxic T lymphocytes (CTLs).
To present antigen at the cell surface, major histocompatibility
complex (MHC) class I heavy chains must form a complex with the light
chain,
2-microglobulin
(
2m), and peptide to acquire a stable
conformation. MHC class I-associated peptides are generated in the
cytoplasm mainly by the proteasome and are transported into the
endoplasmic reticulum (ER) by the transporter TAP (transporter associated with antigen processing). Once in the ER, the peptides are
loaded onto MHC class I molecules. Stable class
I-
2m-peptide complexes then traverse
the Golgi en route to the cell surface, where they can interact with
CD8+ CTLs.
Herpesvirus gene products influence MHC class I antigen presentation in
numerous and diverse ways. Some herpesvirus proteins interfere with
proteolysis of antigens (13) or peptide transport into the
ER (3, 15, 33, 40). Others retain or destroy class I
molecules (2, 19, 37, 41), enhance the internalization of
class I molecules (12, 17, 31), or divert class I
molecules to lysosomes for degradation (30; for reviews,
see references 4 and 34). Judging from the
number and molecular diversity of these strategies, the removal of MHC
class I-peptide complexes from the cell surface must be evolutionarily
advantageous to these viruses as a means of escaping immune detection.
Most of the immunoevasins encoded by herpesviruses are unique, yet all
herpesviruses analyzed manage to interfere with class I antigen
presentation in one way or another. No obvious homologies are apparent
between any HHV-6 or -7 genes and the genes that encode immunoevasins
in other herpesviruses; nonetheless it seemed likely that HHV-6 and -7 also encode immunoevasins. Here we describe a gene product from HHV-7
that binds tightly to properly folded MHC class I molecules and diverts
them to lysosomes.
 |
MATERIALS AND METHODS |
Cell lines.
SupT1 cells were cultured in RPMI-5% fetal
bovine serum and were infected by coculturing with HHV-7 (strain
SB)-infected SupT1 cells (P. Pellett, Centers for Disease Control and
Prevention, Atlanta, Ga.) (1). Infected cells were used
for experiments 2 to 6 days postinfection. U373 astrocytoma cells were
cultured in Dulbecco's modified Eagle medium (DMEM)-10% fetal
bovine serum. U373 astrocytoma cells were infected with a retrovirus
encoding U21 or U21 with an influenza virus hemagglutinin (HA) epitope tag.
Antibodies.
W6/32 is a monoclonal antibody (MAb) that
recognizes assembled,
2m-associated HLA-A, -B,
or -C molecules (6). For some immunofluorescence studies,
W6/32 was covalently coupled to Alexa Fluor 488 dye (Molecular Probes,
Eugene, Oreg.). 12CA5 is a MAb that recognizes the influenza virus HA
epitope tag. Antibody (Ab) 2441 is a rabbit polyclonal Ab that was
raised against glutathione S-transferase (GST) fused in
frame to the C terminus of U21. The FITC-conjugated HLA-A-B-C Ab was
purchased from PharMingen. The MAb
-EEA1 was obtained from Becton
Dickinson, Lexington, Ky., anti-
-adaptin MAb 100/3 was purchased
from Sigma (St. Louis, Mo.).
-lamp1 and -lamp2 MAbs were the
generous gift of T. August (Johns Hopkins Medical School), and the
polyclonal CI-M6PR Ab recognizes the cation-independent mannose
6-phosphate receptor (14). The 66Ig10 MAb recognizes the
transferrin receptor (35). Alexa- or FITC-conjugated
secondary antibodies were purchased from Molecular Probes or Jackson
Immunologicals (West Grove, Pa.). Alexa 488 was covalently coupled to
the W6/32 MAb according to the manufacturer's instructions.
Pulse-chase experiments.
Cells were detached with trypsin
and incubated with methionine- and cysteine-free DMEM for 30 min at
37°C. Cells were labeled with 500 or 1,000 µCi of
[35S]methionine-cysteine (1,200 Ci/mmol;
NEN-Dupont, Boston, Mass.) per milliliter at 37°C for the indicated
times and chased with complete DMEM supplemented with nonradiolabeled
methionine and cysteine to a final concentration of 1 mM at 37°C for
the indicated times. Cells were lysed in digitonin lysis buffer (1%
digitonin, 25 mM HEPES [pH 7.7], 150 mM potassium acetate) or Nonidet
P-40 lysis buffer (50 mM Tris-HCl [pH 7.4], 0.5% NP-40, 5 mM
MgCl2). Lysates were centrifuged for 5 to 10 min
at 14,000 rpm at 4°C in an Eppendorf model 5415C centrifuge to
pellet nuclei and debris, and precleared with protein A-agarose (BRL
Life Sciences, Grand Island, N.Y.) and 3 µl of normal mouse serum,
followed by immunoprecipitation with specific antiserum and protein
A-agarose. Immunoprecipitations were normalized to equal
trichloroacetic acid-precipitable 35S-labeled
protein. The immunoprecipitates were washed five times with 1 ml of
digitonin wash buffer (0.2% digitonin, 25 mM HEPES [pH 7.7], 150 mM
potassium acetate) or NP-40 wash buffer (50 mM Tris-HCl [pH 7.4],
0.5% NP-40, 5 mM EDTA, 150 mM NaCl) and subjected to sodium dodecyl
sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) or
one-dimensional isoelectric focusing (IEF). Leupeptin (Sigma), in dimethyl sulfoxide, was added to the cells 45 min prior to the pulse
at a final concentration of 200 µM. Concanamycin B (ConB) (Ajinimoto
Co., Kanagawa, Japan) (39) was added to the cells 45 min
prior to the pulse at 20 nM final concentration. Brefeldin A
(BFA) (Sigma), was added to the pulse and chase medium at a final concentration of 10 µg/ml 5 min prior to the start of the chase
period. Endoglycosidase Hf (New England Biolabs,
Beverly, Mass.) was added to the immunoprecipitates according to the
vendor's instructions.
Cloning of U20 and U21.
PCR amplification of U20 and U21 was
performed from cDNA made from infected SupT1 cells, which yielded DNA
fragments of the predicted sizes. The resulting fragments were cloned
into the PCR-Blunt II TOPO-expression vector (Invitrogen), and the
sequences were confirmed. PCR was performed from cDNA made from
HHV-7-infected cells using the following primers corresponding to the
5' and 3' ends of the U21 and U20 open reading frames (nucleotides
31242 to 32431 (U20) and 32422 to 33714 (U21) from HHV-7, strain RK): U20, 5'-gccaccATGTTTGTGAAAAAAAC-3' and
5'-ccTTAATGACACATGAAATCT-3'; U21,
5'-gccaccATGTGGACTATCTTGCTGTTTT-3' and
5'-TAATCACAAACATTGCTGT-3'. The U20 and U21 cDNAs were then
subcloned into the retroviral vector LNCX (Clontech, Palo Alto,
Calif.). HA-tagged U20 and U21 were amplified from primers containing
the additional HA sequence: GCCTACCCATACGACGTACCAGACTACGCA.
Flow cytometry.
Cells were removed from the plates with
phosphate-buffered saline (PBS)-1 mM EDTA, washed with ice-cold PBS,
and incubated with FITC-conjugated anti-HLA-A-B-C Ab or with the 66IG10
monoclonal anti-transferrin receptor Ab for 30 min on ice, washed
thoroughly, and either resuspended in ice-cold PBS or incubated with
FITC-conjugated goat anti-mouse secondary Ab and washed again before
evaluating the surface levels of fluorescence with a Beckman
FACScalibur flow cytometer.
Immunofluorescence microscopy.
Cells on coverslips were
washed with PBS and fixed with 3% paraformaldehyde for 10 min;
permeabilized with 0.5% saponin or NP-40 in PBS and 3% BSA or 2%
fish skin gelatin; incubated with primary antibodies or Alexa
488-conjugated W6/32 for 30 min; washed; incubated with FITC-, Alexa
488-, or Alexa 598-conjugated secondary antibodies for 30 min;
washed; and mounted on microscope slides.
 |
RESULTS |
HHV-7 infection in vitro is limited to primary
CD4+ T cells and the SupT1 thymocyte-derived
T-cell line (1, 7). One of the limitations to working with
HHV-7 is that attempts at preparation of a high-titer cell-free virus
have been unsuccessful (for a review, see reference 9). As
is the case for varicella-zoster virus and HCMV, HHV-7 infection is
best spread via cell-cell contact (1); thus, infection of
cultured SupT1 cells is accomplished by mixing SupT1-infected with
noninfected cells at a ratio of 1:5. An average of 30% of these cells
become positive for an HHV-7 nuclear antigen (8), a source
of some variability in the outcome of biochemical analysis. Cytomegaly
and syncytium formation provide a more rapid indication of infection efficiency.
A 60-kDa glycoprotein associates tightly with properly folded class
I molecules in HHV-7 infected cells.
To determine whether
infection with HHV-7 affected class I maturation, we immunoprecipitated
MHC class I molecules from
[35S]methionine-labeled HHV-7-infected SupT1 T
cells using the conformation-specific class I Ab W6/32, which
recognizes only properly folded class I-
2m
complexes. In HHV-7-infected cells, where approximately 50 to 60% of
the cells exhibited cytomegaly, we observed a coimmunoprecipitating protein of approximately 60 kDa (Fig. 1,
lanes 4 to 6), which was absent from noninfected SupT1 cells (Fig. 1,
lanes 1 to 3). This coprecipitating protein, designated gp60,
associated with class I molecules soon after synthesis, since this
association was already apparent after a 10-min pulse-label period
(Fig. 1, lane 4). The class I-associated polypeptide became more
diffuse at later chase times, suggesting heterogeneous glycosylation
upon traversal of the secretory pathway (Fig. 1, lanes 5 and 6). In infected cells, the amount of immunoprecipitated class I heavy chain
molecules decreased in the course of the chase period, compared to
noninfected cells (lanes 6 and 3), suggesting destabilization of class
I molecules. After 90 min of chase, the amount of W6/32-reactive class
I heavy chain was reduced, but the amount of gp60 recovered by W6/32
coimmunoprecipitation increased (lanes 4 to 6). A pool of free
radiolabeled gp60, synthesized during the pulse and capable of
interacting with unlabeled class I molecules synthesized during the
chase, would explain this observation. The polypeptides of low
molecular weight in lanes 5 and 6 may represent degradation products of the class I heavy chain that retain the W6/32 epitope. Alternatively, they could be fragments of gp60 that continue to associate with class I molecules. We have not pursued the
identification of these polypeptides further.

View larger version (52K):
[in this window]
[in a new window]
|
FIG. 1.
A 60-kDa protein associates tightly with MHC class I
complexes in HHV-7-infected cells. Noninfected or HHV-7-infected SupT1
cells (72 h postinfection) were pulse-labeled for 10 min and then
chased for the indicated times. The cells were washed, lysed, and
immunoprecipitated with W6/32. The class I heavy chain and gp60 are
indicated. Asterisks denote degradation products.
|
|
The association between the 60-kDa protein and MHC class I is strong,
as it persisted through four washes with lysis buffer
containing 0.01%
SDS (data not shown). gp60 did not coimmunoprecipitate
with normal
mouse serum and thus is not an Fc receptor, nor did
it coprecipitate
with anti-transferrin receptor antibodies. Finally,
antisera directed
against free class I heavy chains failed to
recover gp60 from
HHV-7-infected cells (data not shown), suggesting
that gp60 binds
exclusively to properly folded
2m-bound class
I
molecules.
gp60 contains multiple N-linked glycans and is further modified in
the Golgi.
Endoglycosidase H (Endo-H) cleaves high-mannose
N-linked glycans found on proteins in the ER and early Golgi. Transport
of glycoproteins through the medial Golgi usually results in resistance to Endo-H, the consequence of complex-type glycan modifications. To
determine whether gp60 contained N-linked oligosaccharide modifications and whether gp60 affected the trafficking of class I molecules through
the Golgi, we performed a pulse-chase experiment identical to that
described in Fig. 1 and treated the immunoprecipitated samples with
Endo-H (Fig. 2A). Most newly synthesized
glycoproteins remain in the ER and are Endo-H sensitive after 10 min of
pulse-labeling with [35S]methionine. When W6/32
immunoprecipitates were treated with Endo-H, the single N-linked glycan
on the class I heavy chain was removed (Fig. 2A, compare lanes 1 and
4). Some Endo-H-resistant heavy chain molecules were present in this
experiment after only 10 min of labeling (lane 4, HCr). gp60 is also Endo-H sensitive; the 60-kDa
polypeptide appears to collapse to a molecular mass coincident with
Endo-H-resistant class I heavy chains (Fig. 2A, compare lanes 10 and
7). After a 30-min chase period, a greater percentage of MHC class I
heavy chain molecules are Endo-H resistant (lane 5), and we begin to see the appearance of Endo-H-resistant gp60 molecules (lane 11). gp60
appears to have two Endo-H-resistant forms, consistent with incomplete
conversion of at least one of its glycans. In contrast to the
experiments depicted in Fig. 1, little gp60 was visible in association
with class I molecules after the pulse-label (compare Fig. 2A, lane 7, with Fig. 1, lane 4). We attribute this to poor infection efficiency of
the cells used in Fig. 2A, as judged by the low percentage (20 to 30%)
of cells exhibiting the characteristic HHV-7-associated cytomegaly.

View larger version (49K):
[in this window]
[in a new window]
|
FIG. 2.
The MHC class I-associated protein is a glycoprotein.
(A) HHV-7-infected SupT1 cells (72 h postinfection) were pulse-labeled
for 10 min and then chased for the indicated times. W6/32 immune
complexes were digested with or without Endo-H. Endo-H-resistant forms
of MHC class I heavy chain (HCr) and gp60
(gp60r1 and gp60r2) are indicated. (B)
HHV-7-infected SupT1 cells were pulse-labeled for 10 min and then
chased for the indicated times in the absence or presence of BFA and
immunoprecipitated with W6/32. (C) HHV-7-infected SupT1 cells were
pulse-labeled for 10 min and then chased for 40 min in the presence of
BFA. W6/32 immune complexes were treated with increasing concentrations
of Endo-H, as indicated. The estimated number of glycans added to gp60
are indicated on the right.
|
|
Its diffuse nature on SDS-polyacrylamide gels suggested that gp60
contains complex-type N-linked glycans. When HHV-7-infected
cells were
treated with BFA, which inhibits ER-to-Golgi traffic
and results in the
redistribution of Golgi membranes and resident
enzymes into the ER
(
22), gp60 presented as a more discrete
polypeptide,
consistent with the normal occurrence of complex-type
oligosaccharide
modifications on gp60 (Fig.
2B). We conclude that
gp60 and the class I
products with which it associates form a
complex early in biosynthesis
and travel together through the
secretory pathway. In this experiment,
the percentage of HHV-7-infected
cells was similar to that shown in
Fig.
2A.
Glycoproteins remain mostly Endo-H sensitive in BFA-treated cells;
thus, BFA treatment should also increase the fraction of
Endo-H-sensitive glycoproteins. To determine the number of N-linked
glycans added to gp60, class I-gp60 complexes were recovered from
HHV-7-infected cells treated with BFA to prevent addition of
complex-type
N-linked glycans. The immune complexes were then treated
with
a range of concentrations of Endo-H. At the highest Endo-H
concentration,
a fully deglycosylated polypeptide of approximately 45 kDa became
apparent (Fig.
2C). Combined with the estimated loss of
~15 kDa
for the fully deglycosylated species, we infer the presence
of
three or four N-linked glycans, although the exact number could
not
be verified
experimentally.
Identification of the candidate gene that specifies gp60.
The
DNA sequence of HHV-7 is known, and homologies between HHV-7 genes and
other herpesvirus genes have been assigned (24, 25). The
HHV-7 genome does not contain genes that are homologous to any of the
HCMV genes whose products bind to MHC class I molecules. In HCMV, these
genes are located in the unique short region of the genome, a region
without an equivalent in the smaller HHV-7 genome. We therefore
surmised that an HHV-7 gene encoding an MHC class I binding protein
might be unique to HHV-7.
Based on the predicted molecular mass of the endo H-treated
45-kDa polypeptide, there were eight candidate open reading frames
for
the MHC class I-associated protein in the HHV-7 genome (Table
1). Of these, four fulfilled the
criterion of possessing at least
three consensus N-linked glycosylation
sites. Two of the four
candidate genes, U45 and U60, were homologs of
genes conserved
among all herpesviruses and predicted to be involved in
DNA packaging
or nucleotide catabolism. These were not further
considered. The
remaining two open reading frames, U20 and U21, had no
obvious
counterparts in HCMV or other herpesviruses, and thus were
attractive
candidates for the gene encoding gp60.
PCR amplification of U20 and U21 was performed from cDNA isolated from
infected SupT1 cells, yielding DNA fragments of the
predicted sizes.
HA-tagged and nontagged U20 and U21 retroviral
expression vectors were
generated and used to stably transduce
human U373 astrocytoma cells,
which express high levels of MHC
class I products. Immunoprecipitation
of class I MHC products
from U21-expressing cells yielded a protein of
an apparent molecular
weight identical to that of gp60 recovered from
HHV-7 infected
cells (Fig.
3A). Moreover,
immunoprecipitation using an anti-HA
Ab yielded the same 60-kDa
polypeptide, together with material
of a molecular mass corresponding
to that of MHC class I heavy
chain. Expression of U20 did not result in
coimmunoprecipitation
of the HA-tagged U20 protein with MHC class I
heavy chain when
precipitated with the W6/32 class I Ab, nor did the
HA-tagged
U20 comigrate at the same molecular weight as gp60 when it
was
precipitated with the anti-HA antiserum (Fig.
3B). The
coprecipitating
polypeptide in the HA-U20 lane is not the MHC class I
heavy chain,
as this polypeptide migrates slightly faster than MHC
class I
molecules (lane 8). It could be a degradation product of
HA-U20.

View larger version (35K):
[in this window]
[in a new window]
|
FIG. 3.
Coimmunoprecipitation of U21, but not U20, with class I
molecules from astrocytoma cells. (A and B) Cells expressing
C-terminally HA epitope-tagged U20 (A), U21-HA (B), or retroviral
vector alone (LNCX) were labeled for 1 h with
[35S]methionine, lysed, and immunoprecipitated with
either W6/32 or an anti-HA Ab. The asterisk denotes a probable
degradation product of U20 that is smaller than the class I heavy
chain. (C) Amino acid sequence of U21. The predicted signal sequence
(continuous line) and transmembrane region (dashed line) are
underlined. Predicted N-glycosylation sites are circled. (D) Schematic
representation of sequence in panel C, with the predicted signal
sequence shaded and the transmembrane region hatched.
|
|
The relative amount of U21 that coimmunoprecipitated with class I from
retrovirally infected U21 astrocytoma cells is comparable
to that seen
in HHV-7-infected SupT1 cells. The retrovirally transduced
U21 levels
could therefore be in the approximate range of physiological
U21
expression levels seen in HHV-7-infected cells. No homologies
were
apparent between U21 and any other protein, except between
that of its
counterpart in the colinear genome of HHV-6. Four
of the five potential
N-linked glycosylation sites in the U21
sequence are N-terminal to the
predicted transmembrane domain
(Fig.
3C). Since U21 is glycosylated at
least three times (Fig.
2B), we infer it to be a type I membrane
protein with a predicted
cleavable signal sequence (
26),
four potential N-linked glycosylation
sites, and a short cytoplasmic
tail (Fig.
3D).
Ab directed against U21.
We raised a rabbit antiserum directed
against the cytoplasmic tail of U21 fused at its N terminus to GST.
This antiserum immunoprecipitates a protein with mobility identical to
that of the U21 recovered in a complex with class I molecules from U21
retrovirus-transduced U373 cells (Fig.
4A, lane 4). The protein recovered by the
antiserum to U21 was indistinguishable in size from that isolated from
HHV-7-infected SupT1 cells. However, the U21 product in astrocytoma
cells appeared less diffuse than in HHV-7-infected SupT1 T cells
(compare Fig. 1, lane 5, with U21 in Fig. 3B or 4A). This discrepancy
may be due to inherent differences in complex-type glycan modifications that occur in the two cell lines. These data confirm that U21 is indeed
the MHC class I-associated protein and further demonstrate that U21 can
associate with MHC class I complexes in the absence of other
HHV-7-encoded proteins.

View larger version (56K):
[in this window]
[in a new window]
|
FIG. 4.
U21 does not discriminate against the products of
different class I loci. (A) Class I complexes from control and
U21-expressing cells were precipitated with either W6/32 or a
polyclonal anti-U21 Ab and separated by SDS-PAGE. (B) IEF gel of W6/32
and -U21 immunoprecipitations shown in panel A. Lanes 3, 4, 7, and 8 are from the same samples as those in lanes 1 to 4 from the SDS-PAGE
gel in panel A. Heavy chains of class I (HC), 2m, and
sialylated class I heavy chain molecules are indicated.
|
|
U21 associates with multiple alleles of MHC class I.
The human
MHC encodes three class I heavy chain gene products, termed HLA-A, -B,
and -C. These genes are highly polymorphic; thus, most human cell lines
would be expected to possess two different alleles of each heavy chain
gene. The generation of anti-U21 serum allowed us to ask whether all
MHC class I products associate equally well with U21. To resolve the
MHC class I allelic products immunoprecipitated by W6/32 and U21, we
employed one-dimensional IEF gels. Immunoprecipitations were carried
out from 35S-labeled control and U21-expressing
cells using the W6/32 and U21 antibodies. The same immunoprecipitate
shown in Fig. 4, lane 1, was resolved on an IEF gel, where the class I
heavy chains resolve as multiple bands, reflecting the presence of
multiple distinct class I products in the U373 cell line. As MHC class I heavy chains acquire sialic acids in the course of their maturation, polypeptides that focus at more acidic isoelectric point are visible at
later time points. The immunoprecipitation from control cells using the
U21-specific Ab is predictably devoid of bands in both SDS-PAGE and IEF
gels (lanes 2 and 8). The pattern of bands precipitated with W6/32
(lanes 3 and 11) from U21-expressing cells is essentially indistinguishable from that in control cells (lanes 1 and 7), with the
exception of some heterodisperse material at the top of the lanes from
U21 cells. This is likely to be U21 itself, since the predicted pI of
U21 is 7.5, outside of the resolvable pH range of the gel system used.
IEF of the U21 immunoprecipitates from U21 cells (lanes 4 and 12) shows
an almost identical pattern of heavy chains to that of W6/32
immunoprecipitates from control cells (lane 7), indicating that U21
associates with the same allelic class I products that are
immunoprecipitated with W6/32. We conclude that U21 interacts with all
of the major class I products in SupT1 cells. The allelic class I
products expressed by SupT1 cells have not been identified. The
acquisition of sialic acids on class I heavy chains is not impeded by
the presence of U21. Likewise, U21-associated heavy chains are
sialylated. Thus, the presence of U21 does not interfere with
passage of class I heavy chains through the Golgi.
ConB prevents degradation of U21 and class I molecules.
One of
the viral gene products from mouse cytomegalovirus (mCMV) that
downregulates MHC class I, designated m06, diverts MHC class I
molecules to the lysosomes for degradation (30). HHV-7 infection results in the loss of recovery of pulse-labeled MHC class I
molecules, possibly due to degradation (Fig. 1). Degradation must occur
after the complex has received complex-type oligosaccharide modifications in the Golgi, since the acquisition of Endo-H resistance for both class I and U21 (Fig. 2A) and the presence of sialic acids on
U21-associated class I products (Fig. 4B) is inconsistent with
retention of this complex in the ER. We therefore examined whether MHC
class I complexes in HHV-7-infected cells could be stabilized in the
presence of ConB, an inhibitor of the vacuolar H+-ATPase. Lysosomal protease function is
compromised at more neutral pH, and thus stabilization of a protein in
the presence of ConB would suggest involvement of lysosomal proteases
in the turnover of that particular protein. MHC class I molecules in
HHV-7-infected cells were stabilized in the presence of ConB (Fig.
5A, compare lanes 5 and 6 with lanes 8 and 9). Thus, elevation of intraorganellar pH stabilizes MHC class I
molecules in HHV-7-infected cells.

View larger version (44K):
[in this window]
[in a new window]
|
FIG. 5.
ConB prevents degradation of U21 and class I molecules.
(A) HHV-7-infected SupT1 cells (72 h postinfection) were pulse-labeled
for 10 min and then chased for the indicated times in the presence of
ConB, lanes 7 to 9. gp60 and class I heavy chains are indicated. (B)
U21-expressing U373 astrocytoma cells were pulse-labeled for 10 min and
then chased for the indicated times in the presence of ConB, lanes 1 to
3 and 7 to 9.
|
|
In astrocytoma cells, U21 expression alone resulted in a reduction in
the levels of class I products (Fig.
5B, lanes 5 and
6), and both class
I and U21 molecules became stabilized with
ConB treatment (Fig.
5B,
compare lanes 5 and 6 with lanes 8 and
9). These observations suggest
that U21 may escort MHC class I
molecules to an acidic compartment,
where they are
destroyed.
U21 expression results in redistribution of MHC class I molecules
to lysosomes.
A lysosomal targeting function for U21 should
manifest itself in a redistribution of class I molecules complexed with
U21. The HHV-7-permissive SupT1 T cells are not conducive to
satisfactory morphological analysis, as they possess only a thin shell
of cytoplasm around the nucleus. We therefore focused on the
U21-expressing adherent U373 astrocytoma cell line for
immunocytochemistry. Immunofluorescence microscopy was performed on
control and U21-expressing U373 astrocytoma cells using the W6/32 Ab.
Class I immunolabeling of control astrocytoma cells shows a typical
plasma membrane labeling pattern (Fig.
6a). Weakly labeled intracellular
structures are likely to be the ER and Golgi apparatus. In contrast,
U21-expressing cells exhibit intense perinuclear fluorescent labeling
when analyzed with the W6/32 Ab (Fig. 6b), and plasma membrane labeling
is diminished. Strong perinuclear localization was readily apparent in
HHV-7-infected SupT1 cells as well (data not shown).

View larger version (98K):
[in this window]
[in a new window]
|
FIG. 6.
Immunofluorescence of MHC class I in U373 astrocytoma
cells. Control U373 cells (a) or U21-expressing U373 cells (b) were
labeled with the W6/32 Ab, directed against properly folded MHC class I
molecules. Arrows indicate perinuclear W6/32 labeling that is absent
from control cells.
|
|
In HHV-7 infected cells, MHC class I molecules are diverted to a
lysosomal compartment where they are most likely degraded
(Fig.
5).
Since U21 binds tightly to class I molecules and we
observed
relocalization of W6/32 fluorescence in U21-expressing
cells, it
follows that U21 might be responsible for the rerouting
class I
molecules to lysosomes for degradation. To identify the
perinuclear
organelle to which class I molecules were relocated
in U21 cells, more
extensive immunofluorescent colocalization
experiments were carried out
with W6/32 and antisera directed
against EEA1 as a marker for early
endosomes,

-adaptin for the
trans-Golgi network, cation-independent
mannose-6-phosphate receptor
(CI-M6PR) for late endosomes, and lamp1
and lamp2 for lysosomes
(Fig.
7). The
perinuclearly localized W6/32-reactive class I molecules
are entirely
coincident with the lysosomal markers lamp1 and lamp2,
demonstrating
that U21 expression results in the sequestration
of MHC class I
molecules in a lysosomal compartment. Not all of
the U21 cells appear
to sequester class I molecules (Fig.
7g and
m). This variation is
likely due to variability in U21 expression
levels in the retrovirally
transduced pools of cells. The U21-specific
antiserum (Fig.
4) did not
yield signals in immunofluorescence
labeling experiments, so
localization of U21 itself could not
be directly verified.

View larger version (34K):
[in this window]
[in a new window]
|
FIG. 7.
Colocalization of MHC class I and lysosomal marker
proteins. U21-expressing U373 cells were labeled with antisera directed
against W6/32 (left panels) and the marker proteins EEA1, -adaptin,
CI-M6PR, and lamp-1 and -2 (middle panels). The left column shows W6/32
immunolabeling. The right column shows merged images. Arrows indicate
specific points of colocalization between the lamp-1 and lamp-2 Ab
labeling and W6/32 labeling. Arrowheads denote cells that are assumed
not to express U21.
|
|
U21 expression results in reduced class I on the cell surface.
With most of the class I molecules sequestered in a lysosomal
compartment in the U373-U21 cell line, the number of class I molecules
at the plasma membrane of U21-expressing cells should be reduced.
Fluorescence-activated cell sorter analysis of neomycin-resistant pools
of retrovirally transduced U21 astrocytoma cells shows that this is
indeed the case (Fig. 8). In
U21-expressing cells, some cells exhibit greatly reduced surface
labeling with W6/32, while others display intermediate levels (Fig.
8A). This variation in cell surface class I expression is likely
attributable to differences in U21 expression levels, since subcloning
of neomycin-resistant cells resulted in the generation of some clonal
cell lines in which the entire population of cells exhibited a more
homogeneous reduction in surface expression of class I products (Fig.
8B). Even this clonal population of cells does not appear entirely homogeneous. Although the retrovirally transduced cell lines were maintained under selective pressure, for unknown reasons, surface expression of class I molecules in this clonal population increased with time in culture and later altogether discontinued expression of
U21. U21 appears specific for MHC class I molecules, since the level of
surface transferrin receptors in U21-expressing cells was
indistinguishable from that in control cells (Fig. 8C).

View larger version (14K):
[in this window]
[in a new window]
|
FIG. 8.
MHC class I surface expression is downregulated in U21
cells. (A) Control U373 cells (red) or U21-expressing astrocytoma cells
(blue) were incubated with a FITC-conjugated anti-HLA-A-B-C Ab and
analyzed by flow cytometry. Fluorescence-activated cell sorter profiles
of cells incubated without FITC-conjugated Ab are in black. (B) A
clonal population of U21-expressing cells is indicated by the green
trace. (C) Surface expression of transferrin receptor is unaffected by
U21 expression.
|
|
 |
DISCUSSION |
Here we demonstrated degradation of MHC class I molecules in cells
infected with HHV-7. We identified the HHV-7 U21 gene product as the
protein responsible for this degradation. The U21-encoded protein is a
transmembrane glycoprotein that associates tightly with properly folded
MHC class I molecules shortly after synthesis in the ER. Expression of
U21 results in the sequestration of class I molecules to a lysosomal
compartment and presumably reduces the number of class I molecules
available to present antigen to CTLs at the cell surface.
The identification of the U21 gene as the MHC class I binding protein
was based on its molecular weight and the number of predicted N-linked
glycans in its primary sequence, both of which were consistent with the
properties of gp60 recovered in a complex with class I molecules.
Infection of astrocytoma cells with a retrovirus specifying the
production of U21 resulted in expression of a protein product
indistinguishable from that recovered in HHV-7-infected cells,
including its tight association with properly folded class I molecules.
Antisera directed against a GST fusion protein with the predicted C
terminus of U21 confirmed the identification of U21 as the correct gene.
There are no obvious predicted sequence homologies between U21 and any
other protein, other than that of the U21 encoded by the colinear
genome of HHV-6. Although HHV-6 U21 is approximately 50% conserved
with HHV-7 U21 at the amino acid level, immunoprecipitations of MHC
class I products have so far failed to yield coprecipitation of U21
from HHV-6-infected cells.
The m06 gene product from murine cytomegalovirus (MCMV) has been shown
to bind to and redirect MHC class I molecules to lysosomes (30). HHV-7 U21 appears functionally similar to the mCMV
m06 gene product, although the two proteins share no homology. The hydropathy profile of m06 suggests that it, too, is a type I membrane protein. Both the m06 and U21 gene products possess multiple
N-glycosylation sites. U21 binds to a similar array of class I gene
products as the HLA-A-B-C-reactive W6/32 Ab, and expression of U21 in
astrocytoma cells results in degradation of all of them. Presumably
MCMV m06 also displays no MHC allele specificity in its binding, since m06 expression results in surface downregulation of multiple class I
alleles in NIH 3T3 cells (30).
MCMV m06 possesses within its C-terminal tail a dileucine sorting
signal that is responsible for targeting the m06 class I complex to
lysosomes (30). Most lysosomal targeting signals contain a
tyrosine, a dileucine sequence, or clusters of acidic amino acids
(10, 16, 21, 27, 28, 36; for reviews, see references
20 and 23) (Table
2. ). The C terminus of U21 possesses
none of these sequences. A dilysine sequence, usually located at the
3 and
4 positions from the extreme carboxyl terminus of a protein,
is responsible for ER retention of some ER resident proteins
(18). U21 does possess a pair of lysines in its C
terminus, but these are not at positions
3 and
4. The metabotropic
glutamate receptor contains a dilysine ER retention sequence that is
not located at the extreme C terminus of its cytoplasmic tail
(11), but this retention sequence also requires the
presence of two proximal arginine residues (RRKK). The two lysines in
the cytoplasmic tail of U21 are not adjacent to arginine residues.
Thus, unlike MCMV m06, U21 does not seem to possess an obvious
predicted sorting signal in its cytoplasmic tail.
U21 acquires endo H resistance after a 30-min chase period (Fig. 2A),
and U21-associated class I molecules acquire sialic acids within the
same time period (Fig. 4B), indicating that U21 proceeds in complex
with class I molecules at least as far as the trans-Golgi. Its tight
association with lysosome-destined MHC class I molecules suggests that
U21 accompanies class I to lysosomes. Furthermore, in U21-expressing
astrocytoma cells treated with ConB, the U21-class I complex is
stabilized, suggesting that both U21 and MHC class I are degraded
together in an acidic compartment (Fig. 5B). The possibility that U21
might shuttle between the trans-Golgi network and an acidic compartment
to accomplish delivery of class I molecules to lysosomes deserves to be
examined further.
We suggest that the HHV-7 gene product U21 functions in the course of
the HHV-7 life cycle to divert MHC class I molecules to the lysosomes
for degradation and in so doing allows the HHV-7-infected cell to
bypass surveillance by CTLs. The specific mechanism by which U21
redirects class I molecules remains to be elucidated. It is not clear
whether U21 accompanies class I molecules to the cell surface or
whether it diverts class I molecules directly to the lysosome from the
Golgi, though the absence of class I molecules from the plasma membrane
of U21-expressing cells at steady state suggests that the diversion is
less likely to involve trafficking via the plasma membrane. U21 may
contain a novel lysosomal targeting sequence, or, equally intriguing,
it may cause a conformational change in the class I molecule that
prevents its interaction with a cellular trafficking protein, or act as
an adapter to connect MHC class I molecules to a cellular protein that
directs it to lysosomes.
 |
ACKNOWLEDGMENTS |
We thank Phil Pellett (Centers for Disease Control and
Prevention) and Jodi Black (National Institutes of Health) for the HHV-7-infected cells, HHV-7-specific antisera, and helpful discussions and Domenic Tortorella, Susanne Wells, and Patricio Meneses for critical reading of the manuscript and helpful discussions.
A.W.H. is supported by a fellowship from the Irvington Institute for
Immunological Research (New York, N.Y.). This work was supported by NIH
grant PO1-AI-42257 (to P.M.H. and H.L.P.).
 |
FOOTNOTES |
*
Corresponding author. Mailing address: Department of
Pathology, Harvard Medical School, 200 Longwood Ave., Boston, MA
02115. Phone: (617) 432-2892. Fax: (617) 432-0727. E-mail:
ahudson{at}hms.harvard.edu.
 |
REFERENCES |
| 1.
|
Ablashi, D. V.,
M. Handy,
J. Bernbaum,
L. G. Chatlynne,
W. Lapps,
B. Kramarsky,
Z. N. Berneman,
A. L. Komaroff, and J. E. Whitman.
1998.
Propagation and characterization of human herpesvirus-7 (HHV-7) isolates in a continuous T-lymphoblastoid cell line (SupT1).
J. Virol. Methods
73:123-140[CrossRef][Medline].
|
| 2.
|
Ahn, K.,
A. Angulo,
P. Ghazal,
P. A. Peterson,
Y. Yang, and K. Fruh.
1996.
Human cytomegalovirus inhibits antigen presentation by a sequential multistep process.
Proc. Natl. Acad. Sci. USA
93:10990-10995[Abstract/Free Full Text].
|
| 3.
|
Ahn, K.,
T. H. Meyer,
S. Uebel,
P. Sempe,
H. Djaballah,
Y. Yang,
P. A. Peterson,
K. Fruh, and R. Tampe.
1996.
Molecular mechanism and species specificity of TAP inhibition by herpes simplex virus ICP47.
EMBO J.
15:3247-3255[Medline].
|
| 4.
|
Alcami, A., and U. H. Koszinowski.
2000.
Viral mechanisms of immune evasion.
Trends Microbiol.
8:410-418[CrossRef][Medline].
|
| 5.
|
Asano, Y.,
S. Suga,
T. Yoshikawa,
T. Yazaki, and T. Uchikawa.
1995.
Clinical features and viral excretion in an infant with primary human herpesvirus 7 infection.
Pediatrics
95:187-190[Abstract/Free Full Text].
|
| 6.
|
Barnstable, C. J.,
W. F. Bodmer,
G. Brown,
G. Galfre,
C. Milstein,
A. F. Williams, and A. Ziegler.
1978.
Production of monoclonal antibodies to group A erythrocytes, HLA and other human cell surface antigens: new tools for genetic analysis.
Cell
14:9[CrossRef][Medline].
|
| 7.
|
Berneman, Z. N.,
D. V. Ablashi,
G. Li,
M. Eger-Fletcher,
M. S. Reitz, Jr.,
C. L. Hung,
I. Brus,
A. L. Komaroff, and R. C. Gallo.
1992.
Human herpesvirus 7 is a T-lymphotropic virus and is related to, but significantly different from, human herpesvirus 6 and human cytomegalovirus.
Proc. Natl. Acad. Sci. USA
89:10552-10556[Abstract/Free Full Text].
|
| 8.
|
Black, J. B.,
D. A. Burns,
C. S. Goldsmith,
P. M. Feorino,
K. Kite-Powell,
R. F. Schinazi,
P. W. Krug, and P. E. Pellett.
1997.
Biologic properties of human herpesvirus 7 strain SB.
Virus Res.
52:25-41[CrossRef][Medline].
|
| 9.
|
Black, J. B., and P. E. Pellett.
1999.
Human herpesvirus 7.
Rev. Med. Virol.
9:245-262[CrossRef][Medline].
|
| 10.
|
Canfield, W. M.,
K. F. Johnson,
R. D. Ye,
W. Gregory, and S. Kornfeld.
1991.
Localization of the signal for rapid internalization of the bovine cation-independent mannose 6-phosphate/insulin-like growth factor-II receptor to amino acids 24-29 of the cytoplasmic tail.
J. Biol. Chem.
266:5682-5688[Abstract/Free Full Text].
|
| 11.
|
Chan, W. Y.,
M. M. Soloviev,
F. Ciruela, and R. A. McIlhinney.
2001.
Molecular determinants of metabotropic glutamate receptor 1B trafficking.
Mol. Cell Neurosci.
17:577-588[CrossRef][Medline].
|
| 12.
|
Coscoy, L., and D. Ganem.
2000.
Kaposi's sarcoma-associated herpesvirus encodes two proteins that block cell surface display of MHC class I chains by enhancing their endocytosis.
Proc. Natl. Acad. Sci. USA
97:8051-8056[Abstract/Free Full Text].
|
| 13.
|
Gilbert, M. J.,
S. R. Riddell,
B. Plachter, and P. D. Greenberg.
1996.
Cytomegalovirus selectively blocks antigen processing and presentation of its immediate-early gene product.
Nature
383:720-722[CrossRef][Medline].
|
| 14.
|
Griffiths, G.,
B. Hoflack,
K. Simons,
I. Mellman, and S. Kornfeld.
1988.
The mannose 6-phosphate receptor and the biogenesis of lysosomes.
Cell
52:329-341[CrossRef][Medline].
|
| 15.
|
Hill, A.,
P. Jugovic,
I. York,
G. Russ,
J. Bennink,
J. Yewdell,
H. Ploegh, and D. Johnson.
1995.
Herpes simplex virus turns off the TAP to evade host immunity.
Nature
375:411-415[CrossRef][Medline].
|
| 16.
|
Honing, S.,
J. Griffith,
H. J. Geuze, and W. Hunziker.
1996.
The tyrosine-based lysosomal targeting signal in lamp-1 mediates sorting into Golgi-derived clathrin-coated vesicles.
EMBO J.
15:5230-5239[Medline].
|
| 17.
|
Ishido, S.,
C. Wang,
B. S. Lee,
G. B. Cohen, and J. U. Jung.
2000.
Downregulation of major histocompatibility complex class I molecules by Kaposi's sarcoma-associated herpesvirus K3 and K5 proteins.
J. Virol.
74:5300-5309[Abstract/Free Full Text].
|
| 18.
|
Jackson, M. R.,
T. Nilsson, and P. A. Peterson.
1990.
Identification of a consensus motif for retention of transmembrane proteins in the endoplasmic reticulum.
EMBO J.
9:3153-3162[Medline].
|
| 19.
|
Jones, T. R.,
E. J. Wiertz,
L. Sun,
K. N. Fish,
J. A. Nelson, and H. L. Ploegh.
1996.
Human cytomegalovirus US3 impairs transport and maturation of major histocompatibility complex class I heavy chains.
Proc. Natl. Acad. Sci. USA
93:11327-11333[Abstract/Free Full Text].
|
| 20.
|
Kirchhausen, T.,
J. S. Bonifacino, and H. Riezman.
1997.
Linking cargo to vesicle formation: receptor tail interactions with coat proteins.
Curr. Opin. Cell Biol.
9:488-495[CrossRef][Medline].
|
| 21.
|
Letourneur, F., and R. D. Klausner.
1992.
A novel di-leucine motif and a tyrosine-based motif independently mediate lysosomal targeting and endocytosis of CD3 chains.
Cell
69:1143-1157[CrossRef][Medline].
|
| 22.
|
Lippincott-Schwartz, J.,
L. Yuan,
C. Tipper,
M. Amherdt,
L. Orci, and R. D. Klausner.
1991.
Brefeldin A's effects on endosomes, lysosomes, and the TGN suggest a general mechanism for regulating organelle structure and membrane traffic.
Cell
67:601-616[CrossRef][Medline].
|
| 23.
|
Marks, M. S.,
H. Ohno,
T. Kirchhausen, and J. S. Bonifacino.
1997.
Protein sorting by tyrosine-based signals: adapting to the Ys and wherefores.
Trends Cell Biol.
7:124-128[Medline].
|
| 24.
|
Megaw, A. G.,
D. Rapaport,
B. Avidor,
N. Frenkel, and A. J. Davison.
1998.
The DNA sequence of the RK strain of human herpesvirus 7.
Virology
244:119-132[CrossRef][Medline].
|
| 25.
|
Nicholas, J.
1996.
Determination and analysis of the complete nucleotide sequence of human herpesvirus.
J. Virol.
70:5975-5989[Abstract].
|
| 26.
|
Nielsen, H.,
J. Engelbrecht,
S. Brunak, and G. von Heijne.
1997.
Identification of prokaryotic and eukaryotic signal peptides and prediction of their cleavage sites.
Protein Eng.
10:1-6[Abstract/Free Full Text].
|
| 27.
|
Ohno, H.,
J. Stewart,
M. C. Fournier,
H. Bosshart,
I. Rhee,
S. Miyatake,
T. Saito,
A. Gallusser,
T. Kirchhausen, and J. S. Bonifacino.
1995.
Interaction of tyrosine-based sorting signals with clathrin-associated proteins.
Science
269:1872-1875[Abstract/Free Full Text].
|
| 28.
|
Peters, C.,
M. Braun,
B. Weber,
M. Wendland,
B. Schmidt,
R. Pohlmann,
A. Waheed, and K. von Figura.
1990.
Targeting of a lysosomal membrane protein: a tyrosine-containing endocytosis signal in the cytoplasmic tail of lysosomal acid phosphatase is necessary and sufficient for targeting to lysosomes.
EMBO J.
9:3497-3506[Medline].
|
| 29.
|
Portolani, M.,
C. Cermelli,
P. Mirandola, and D. Di Luca.
1995.
Isolation of human herpesvirus 7 from an infant with febrile syndrome.
J. Med. Virol.
45:282-283[Medline].
|
| 30.
|
Reusch, U.,
W. Muranyi,
P. Lucin,
H. G. Burgert,
H. Hengel, and U. H. Koszinowski.
1999.
A cytomegalovirus glycoprotein re-routes MHC class I complexes to lysosomes for degradation.
EMBO J.
18:1081-1091[CrossRef][Medline].
|
| 31.
|
Stevenson, P. G.,
S. Efstathiou,
P. C. Doherty, and P. J. Lehner.
2000.
Inhibition of MHC class I-restricted antigen presentation by gamma 2-herpesviruses.
Proc. Natl. Acad. Sci. USA
97:8455-8460[Abstract/Free Full Text].
|
| 32.
|
Tanaka, K.,
T. Kondo,
S. Torigoe,
S. Okada,
T. Mukai, and K. Yamanishi.
1994.
Human herpesvirus 7: another causal agent for roseola (exanthem subitum).
J. Pediatr.
125:1-5[CrossRef][Medline].
|
| 33.
|
Tomazin, R.,
A. B. Hill,
P. Jugovic,
I. York,
P. van Endert,
H. L. Ploegh,
D. W. Andrews, and D. C. Johnson.
1996.
Stable binding of the herpes simplex virus ICP47 protein to the peptide binding site of TAP.
EMBO J.
15:3256-3266[Medline].
|
| 34.
|
Tortorella, D.,
B. E. Gewurz,
M. H. Furman,
D. J. Schust, and H. L. Ploegh.
2000.
Viral subversion of the immune system.
Annu. Rev. Immunol.
18:861-926[CrossRef][Medline].
|
| 35.
|
van M. de Rijn,
A. H. Geurts van Kessel,
V. Kroezen,
A. J. van Agthoven,
K. Verstijnen,
C. Terhorst, and J. Hilgers.
1983.
Localization of a gene controlling the expression of the human transferrin receptor to the region q12 leads to qter of chromosome 3.
Cytogenet. Cell Genet.
36:525-531[Medline].
|
| 36.
|
Voorhees, P.,
E. Deignan,
E. van Donselaar,
J. Humphrey,
M. S. Marks,
P. J. Peters, and J. S. Bonifacino.
1995.
An acidic sequence within the cytoplasmic domain of furin functions as a determinant of trans-Golgi network localization and internalization from the cell surface.
EMBO J.
14:4961-4975[Medline].
|
| 37.
|
Wiertz, E. J.,
D. Tortorella,
M. Bogyo,
J. Yu,
W. Mothes,
T. R. Jones,
T. A. Rapoport, and H. L. Ploegh.
1996.
Sec61-mediated transfer of a membrane protein from the endoplasmic reticulum to the proteasome for destruction.
Nature
384:432-438[CrossRef][Medline].
|
| 38.
|
Wyatt, L. S.,
W. J. Rodriguez,
N. Balachandran, and N. Frenkel.
1991.
Human herpesvirus 7: antigenic properties and prevalence in children and adults.
J. Virol.
65:6260-6265[Abstract/Free Full Text].
|
| 39.
|
Yilla, M.,
A. Tan,
K. Ito,
K. Miwa, and H. L. Ploegh.
1993.
Involvement of the vacuolar H+-ATPases in the secretory pathway of HepG2 cells.
J. Biol. Chem.
268:19092-19100[Abstract/Free Full Text].
|
| 40.
|
York, I. A.,
C. Roop,
D. W. Andrews,
S. R. Riddell,
F. L. Graham, and D. C. Johnson.
1994.
A cytosolic herpes simplex virus protein inhibits antigen presentation to CD8+ T lymphocytes.
Cell
77:525-535[CrossRef][Medline].
|
| 41.
|
Ziegler, H.,
R. Thale,
P. Lucin,
W. Muranyi,
T. Flohr,
H. Hengel,
H. Farrell,
W. Rawlinson, and U. H. Koszinowski.
1997.
A mouse cytomegalovirus glycoprotein retains MHC class I complexes in the ERGIC/cis-Golgi compartments.
Immunity
6:57-66[CrossRef][Medline].
|
Journal of Virology, December 2001, p. 12347-12358, Vol. 75, No. 24
0022-538X/01/$04.00+0 DOI: 10.1128/JVI.75.24.12347-12358.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.
This article has been cited by other articles:
-
Horst, D., van Leeuwen, D., Croft, N. P., Garstka, M. A., Hislop, A. D., Kremmer, E., Rickinson, A. B., Wiertz, E. J. H. J., Ressing, M. E.
(2009). Specific Targeting of the EBV Lytic Phase Protein BNLF2a to the Transporter Associated with Antigen Processing Results in Impairment of HLA Class I-Restricted Antigen Presentation. J. Immunol.
182: 2313-2324
[Abstract]
[Full Text]
-
Mintern, J. D., Klemm, E. J., Wagner, M., Paquet, M. E., Napier, M. D., Kim, Y. M., Koszinowski, U. H., Ploegh, H. L.
(2006). Viral Interference with B7-1 Costimulation: A New Role for Murine Cytomegalovirus Fc Receptor-1. J. Immunol.
177: 8422-8431
[Abstract]
[Full Text]
-
Sadaoka, T., Yamanishi, K., Mori, Y.
(2006). Human herpesvirus 7 U47 gene products are glycoproteins expressed in virions and associate with glycoprotein H.. J. Gen. Virol.
87: 501-508
[Abstract]
[Full Text]
-
Ressing, M. E., van Leeuwen, D., Verreck, F. A. W., Keating, S., Gomez, R., Franken, K. L. M. C., Ottenhoff, T. H. M., Spriggs, M., Schumacher, T. N., Hutt-Fletcher, L. M., Rowe, M., Wiertz, E. J. H. J.
(2005). Epstein-Barr Virus gp42 Is Posttranslationally Modified To Produce Soluble gp42 That Mediates HLA Class II Immune Evasion. J. Virol.
79: 841-852
[Abstract]
[Full Text]
-
Tardif, K. D., Siddiqui, A.
(2003). Cell Surface Expression of Major Histocompatibility Complex Class I Molecules Is Reduced in Hepatitis C Virus Subgenomic Replicon-Expressing Cells. J. Virol.
77: 11644-11650
[Abstract]
[Full Text]
-
Lacayo, J., Sato, H., Kamiya, H., McVoy, M. A.
(2003). Down-regulation of surface major histocompatibility complex class I by guinea pig cytomegalovirus. J. Gen. Virol.
84: 75-81
[Abstract]
[Full Text]